10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)
8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13G - Quince Therapeutics, Inc. (0001662774) (Subject)
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 beginning at 7 a.m. Eastern Time. A webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. About Quince Therapeutics Quince Therapeutics (NASDAQ:QNCX) is a late-stage biotechnology company dedicated to unlocking the power o
Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline Quince recently initiated pivotal Phase 3 NEAT study, which is currently enrolling and being conducted under U.S. FDA Special Protocol Assessment agreement Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the online publication of data in The Lancet Neurology from its Phase 3 ATTeST (Ataxia-Telangiectasia
Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the second quarter ended June 30, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "We achieved a major clinical milestone during the second quarter of 2024 with the first patient enrolled in our pivotal Phase 3 NEAT clinical trial in Ataxia-